Cabaletta Bio(CABA) - 2025 Q4 - Annual Results

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus and PV; anticipating initial RESET-SLE™ data in 1H26 and durability data from the RESET-SLE and RESET-PV ® trials throughout 2026 Exhibit 99.1 Automated manufacturing of rese-cel with Cellares' Cell Shuttle™ un ...